Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Detachment | 15 | 2019 | 88 | 2.750 |
Why?
|
| Vitrectomy | 15 | 2012 | 100 | 2.710 |
Why?
|
| Retinopathy of Prematurity | 11 | 2019 | 88 | 2.400 |
Why?
|
| Vitreous Body | 19 | 2008 | 123 | 1.950 |
Why?
|
| Triamcinolone Acetonide | 7 | 2008 | 38 | 1.810 |
Why?
|
| Retinal Perforations | 6 | 2019 | 31 | 1.590 |
Why?
|
| Retina | 10 | 2019 | 532 | 1.530 |
Why?
|
| Injections | 14 | 2008 | 285 | 1.030 |
Why?
|
| Lens, Crystalline | 6 | 2012 | 155 | 1.010 |
Why?
|
| Endophthalmitis | 6 | 2008 | 84 | 0.990 |
Why?
|
| Visual Acuity | 12 | 2019 | 873 | 0.950 |
Why?
|
| Glucocorticoids | 5 | 2007 | 629 | 0.910 |
Why?
|
| Electroretinography | 8 | 2010 | 116 | 0.900 |
Why?
|
| Laser Coagulation | 4 | 2010 | 136 | 0.720 |
Why?
|
| Refraction, Ocular | 2 | 2010 | 289 | 0.620 |
Why?
|
| Aza Compounds | 3 | 2006 | 25 | 0.600 |
Why?
|
| Anti-Infective Agents | 4 | 2008 | 446 | 0.570 |
Why?
|
| Fluoroquinolones | 5 | 2006 | 126 | 0.540 |
Why?
|
| Quinolines | 3 | 2006 | 383 | 0.470 |
Why?
|
| Fluorescein Angiography | 7 | 2019 | 139 | 0.450 |
Why?
|
| Aqueous Humor | 4 | 2006 | 29 | 0.410 |
Why?
|
| Antifungal Agents | 4 | 2010 | 834 | 0.410 |
Why?
|
| Macular Degeneration | 4 | 2008 | 114 | 0.400 |
Why?
|
| Rabbits | 7 | 2008 | 957 | 0.400 |
Why?
|
| Myopia | 2 | 2010 | 194 | 0.400 |
Why?
|
| Retinal Hemorrhage | 3 | 2011 | 26 | 0.390 |
Why?
|
| Triazoles | 3 | 2004 | 617 | 0.390 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2011 | 1248 | 0.390 |
Why?
|
| Vitreous Detachment | 2 | 2007 | 12 | 0.370 |
Why?
|
| Eye Infections, Fungal | 2 | 2008 | 71 | 0.370 |
Why?
|
| Preservatives, Pharmaceutical | 2 | 2007 | 14 | 0.370 |
Why?
|
| Eye Infections, Bacterial | 2 | 2008 | 96 | 0.350 |
Why?
|
| Suture Techniques | 2 | 2008 | 319 | 0.340 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2008 | 157 | 0.340 |
Why?
|
| Ectopia Lentis | 1 | 2008 | 12 | 0.330 |
Why?
|
| Bacillus cereus | 1 | 2008 | 12 | 0.320 |
Why?
|
| Retinal Vein Occlusion | 1 | 2008 | 29 | 0.320 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2008 | 68 | 0.320 |
Why?
|
| Iris | 1 | 2008 | 67 | 0.310 |
Why?
|
| Retinal Diseases | 3 | 2006 | 179 | 0.300 |
Why?
|
| Chromatography, High Pressure Liquid | 6 | 2008 | 548 | 0.300 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2008 | 163 | 0.300 |
Why?
|
| Gestational Age | 7 | 2006 | 1069 | 0.290 |
Why?
|
| Benzyl Alcohol | 1 | 2006 | 2 | 0.290 |
Why?
|
| Retinal Neovascularization | 1 | 2006 | 20 | 0.290 |
Why?
|
| Pharmaceutical Vehicles | 1 | 2006 | 15 | 0.290 |
Why?
|
| Tomography, Optical Coherence | 4 | 2017 | 501 | 0.290 |
Why?
|
| Fovea Centralis | 1 | 2006 | 23 | 0.280 |
Why?
|
| Telangiectasis | 1 | 2006 | 26 | 0.280 |
Why?
|
| Cryotherapy | 1 | 2006 | 67 | 0.270 |
Why?
|
| Cat-Scratch Disease | 1 | 2005 | 35 | 0.260 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2008 | 314 | 0.250 |
Why?
|
| Triamcinolone | 1 | 2004 | 20 | 0.240 |
Why?
|
| Infant, Newborn | 10 | 2012 | 8223 | 0.240 |
Why?
|
| Lenses, Intraocular | 1 | 2008 | 346 | 0.230 |
Why?
|
| Photochemotherapy | 1 | 2003 | 96 | 0.230 |
Why?
|
| Retinal Vessels | 1 | 2003 | 85 | 0.230 |
Why?
|
| Infant, Very Low Birth Weight | 5 | 2006 | 165 | 0.220 |
Why?
|
| Pyrimidines | 3 | 2004 | 3518 | 0.220 |
Why?
|
| Papilledema | 1 | 2003 | 85 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2011 | 1533 | 0.220 |
Why?
|
| Phacoemulsification | 1 | 2005 | 221 | 0.210 |
Why?
|
| Choroid | 2 | 2017 | 35 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2006 | 994 | 0.200 |
Why?
|
| Osmolar Concentration | 3 | 2008 | 204 | 0.200 |
Why?
|
| Retrospective Studies | 16 | 2019 | 37905 | 0.190 |
Why?
|
| Biological Availability | 4 | 2006 | 214 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 3 | 2008 | 2992 | 0.170 |
Why?
|
| Postoperative Complications | 4 | 2009 | 5542 | 0.170 |
Why?
|
| Male | 25 | 2019 | 123000 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 4367 | 0.160 |
Why?
|
| Treatment Outcome | 11 | 2012 | 32848 | 0.150 |
Why?
|
| Postoperative Period | 2 | 2009 | 665 | 0.150 |
Why?
|
| Half-Life | 2 | 2008 | 259 | 0.150 |
Why?
|
| Intraocular Pressure | 2 | 2008 | 146 | 0.140 |
Why?
|
| Acute Disease | 3 | 2007 | 2422 | 0.140 |
Why?
|
| Choroidal Neovascularization | 2 | 2008 | 29 | 0.140 |
Why?
|
| Humans | 33 | 2019 | 261506 | 0.130 |
Why?
|
| Voriconazole | 3 | 2004 | 108 | 0.130 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2004 | 2063 | 0.130 |
Why?
|
| Animals | 12 | 2010 | 59536 | 0.120 |
Why?
|
| Birth Weight | 2 | 2006 | 374 | 0.120 |
Why?
|
| Follow-Up Studies | 6 | 2012 | 14889 | 0.120 |
Why?
|
| Female | 20 | 2019 | 141928 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2004 | 6150 | 0.120 |
Why?
|
| Fundus Oculi | 2 | 2019 | 74 | 0.110 |
Why?
|
| Central Serous Chorioretinopathy | 1 | 2011 | 7 | 0.100 |
Why?
|
| Aged | 12 | 2019 | 70117 | 0.100 |
Why?
|
| Rats | 3 | 2004 | 6086 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2004 | 1544 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2012 | 16273 | 0.090 |
Why?
|
| Aged, 80 and over | 9 | 2017 | 29902 | 0.090 |
Why?
|
| Disease Progression | 3 | 2019 | 6682 | 0.090 |
Why?
|
| Echinocandins | 1 | 2010 | 132 | 0.090 |
Why?
|
| Bacteria | 2 | 2005 | 611 | 0.090 |
Why?
|
| Sulfur Hexafluoride | 1 | 2008 | 6 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2010 | 6100 | 0.080 |
Why?
|
| Exudates and Transudates | 2 | 2011 | 52 | 0.080 |
Why?
|
| Epiretinal Membrane | 1 | 2008 | 13 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2011 | 3251 | 0.080 |
Why?
|
| Vancomycin | 2 | 2008 | 273 | 0.080 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2008 | 72 | 0.080 |
Why?
|
| Bevacizumab | 2 | 2011 | 938 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 241 | 0.080 |
Why?
|
| Eye | 1 | 2009 | 301 | 0.080 |
Why?
|
| Blindness | 1 | 2008 | 77 | 0.080 |
Why?
|
| Citrus | 1 | 2007 | 7 | 0.080 |
Why?
|
| Crack Cocaine | 1 | 2007 | 5 | 0.080 |
Why?
|
| Ceftazidime | 1 | 2008 | 57 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 4938 | 0.080 |
Why?
|
| Posture | 1 | 2008 | 215 | 0.080 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2007 | 42 | 0.080 |
Why?
|
| Intraoperative Care | 1 | 2008 | 259 | 0.070 |
Why?
|
| Dark Adaptation | 1 | 2006 | 27 | 0.070 |
Why?
|
| Adult | 10 | 2019 | 77950 | 0.070 |
Why?
|
| Cataract | 1 | 2008 | 218 | 0.070 |
Why?
|
| Aphakia, Postcataract | 1 | 2006 | 19 | 0.070 |
Why?
|
| Incidence | 2 | 2007 | 5673 | 0.070 |
Why?
|
| Silicone Oils | 1 | 2005 | 6 | 0.070 |
Why?
|
| Vimentin | 1 | 2007 | 253 | 0.070 |
Why?
|
| Serpins | 1 | 2006 | 77 | 0.070 |
Why?
|
| Vision, Ocular | 1 | 2006 | 157 | 0.070 |
Why?
|
| Bartonella henselae | 1 | 2005 | 23 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2006 | 109 | 0.070 |
Why?
|
| Photic Stimulation | 1 | 2006 | 259 | 0.070 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 8865 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2009 | 411 | 0.070 |
Why?
|
| Florida | 1 | 2005 | 113 | 0.070 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 85 | 0.060 |
Why?
|
| Neuroglia | 1 | 2007 | 223 | 0.060 |
Why?
|
| Fluorocarbons | 1 | 2005 | 63 | 0.060 |
Why?
|
| Candidiasis | 1 | 2007 | 262 | 0.060 |
Why?
|
| Time Factors | 4 | 2019 | 12926 | 0.060 |
Why?
|
| Macular Edema | 1 | 2006 | 99 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 461 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 231 | 0.060 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 101 | 0.060 |
Why?
|
| Eye Proteins | 1 | 2006 | 269 | 0.060 |
Why?
|
| Photography | 1 | 2005 | 139 | 0.060 |
Why?
|
| Porphyrins | 1 | 2003 | 37 | 0.060 |
Why?
|
| Child | 5 | 2019 | 29154 | 0.060 |
Why?
|
| Photosensitizing Agents | 1 | 2003 | 71 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2004 | 682 | 0.060 |
Why?
|
| Antibodies, Bacterial | 1 | 2005 | 380 | 0.060 |
Why?
|
| Enterococcus faecium | 1 | 2003 | 46 | 0.060 |
Why?
|
| Coloring Agents | 1 | 2003 | 234 | 0.060 |
Why?
|
| Vancomycin Resistance | 1 | 2003 | 54 | 0.060 |
Why?
|
| Indocyanine Green | 1 | 2003 | 117 | 0.060 |
Why?
|
| Scleral Buckling | 1 | 2002 | 12 | 0.050 |
Why?
|
| Spherocytes | 1 | 2002 | 5 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 2315 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 418 | 0.050 |
Why?
|
| Middle Aged | 8 | 2019 | 86204 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2004 | 1037 | 0.050 |
Why?
|
| Prospective Studies | 4 | 2006 | 12873 | 0.050 |
Why?
|
| Necrosis | 1 | 2003 | 580 | 0.050 |
Why?
|
| Risk Factors | 3 | 2007 | 17523 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2006 | 1694 | 0.050 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 242 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 1304 | 0.050 |
Why?
|
| Intravitreal Injections | 2 | 2011 | 141 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2002 | 477 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2006 | 1616 | 0.040 |
Why?
|
| Infarction | 1 | 2017 | 31 | 0.040 |
Why?
|
| Bacteremia | 1 | 2003 | 689 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2004 | 1648 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 4744 | 0.040 |
Why?
|
| Macula Lutea | 1 | 2017 | 47 | 0.040 |
Why?
|
| Giant Cell Arteritis | 1 | 2017 | 57 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 7548 | 0.030 |
Why?
|
| Biomarkers | 1 | 2007 | 5047 | 0.030 |
Why?
|
| Infant | 2 | 2012 | 13310 | 0.030 |
Why?
|
| Texas | 1 | 2005 | 6311 | 0.030 |
Why?
|
| Vitreous Hemorrhage | 2 | 2005 | 11 | 0.030 |
Why?
|
| Subretinal Fluid | 1 | 2011 | 10 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2010 | 114 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 21445 | 0.020 |
Why?
|
| Retinal Ganglion Cells | 1 | 2010 | 144 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 503 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 6942 | 0.020 |
Why?
|
| Beverages | 1 | 2007 | 105 | 0.020 |
Why?
|
| Tonometry, Ocular | 1 | 2006 | 32 | 0.020 |
Why?
|
| Urine | 1 | 2006 | 143 | 0.020 |
Why?
|
| Sputum | 1 | 2006 | 141 | 0.020 |
Why?
|
| Models, Animal | 1 | 2006 | 664 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 2003 | 91 | 0.010 |
Why?
|
| Fungi | 1 | 2004 | 145 | 0.010 |
Why?
|
| Biological Transport | 1 | 2004 | 597 | 0.010 |
Why?
|
| Cryosurgery | 1 | 2002 | 167 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2006 | 1459 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 829 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 31252 | 0.010 |
Why?
|
| Mice | 2 | 2010 | 34495 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2002 | 846 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2002 | 2527 | 0.010 |
Why?
|